Physician Views snap poll – ASCO going virtual becomes a reality for oncologists

With unfortunate inevitability, the American Society of Clinical Oncology (ASCO) announced on Tuesday that due to the impact of the COVID-19 pandemic, its annual meeting will not be held as planned as a physical conference. Instead, the meeting, which was scheduled to be held from May 29 to June 2 in Chicago, IL, will be delivered in a virtual format, with abstracts also published online and in the Journal of Clinical Oncology as per usual. More here.

We are snap-polling oncologists from the US, France, Germany, Italy, Spain and the UK to evaluate community response and the potential implications of this news…

____________

Q. Annual meetings of the American Association of Cancer Research (AACR) and the American Society of Clinical Oncology (ASCO) are among those events that have been affected by the coronavirus [COVID-19] pandemic.

A 'Virtual Annual Meeting Preview' will be hosted by the AACR in April, with the meeting rescheduled (if possible) for August.

The ASCO meeting will take place in a virtual format with its educational programme postponed indefinitely at this time.

Which approach do you favour?

AACR

ASCO

____________

Q. If ASCO is unable to reschedule its educational programme for later in 2020, how much of a loss do you think this will be to the oncologist community?

Marginal

Moderate

Significant

____________

Q. How concerned are you that virtual conference formats may limit discussion around potentially controversial aspects of some datasets?

Not concerned

Moderately concerned

Very concerned

____________

Q. Do you therefore think it is possible that oncologist adoption of certain treatments with new data, which are presented initially at medical meetings held with virtual conference formats, will be slower than would have been otherwise?

No

Yes – in the short term

Yes – in the short and long term

____________

Q. In cases where oncology meetings such as ASCO are held in a virtual format, do you anticipate being more reliant on clinical data and supplementary scientific resources provided by the relevant pharmaceutical company(s)?

No

Moderately so

Significantly so

____________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

To read more Physician Views articles, click here.

Reference Articles